Cargando…
Low molecular weight heparin in the treatment of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome: five case reports
Hepatic sinusoidal obstruction syndrome (HSOS) can be caused by the intake of pyrrolizidine alkaloids (PAs). The disease has a high mortality rate, a poor prognosis and limited treatment options. Managing pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome (PA-HSOS) is a significa...
Autores principales: | Jiang, Minjie, Wang, Luyuan, Du, Xiaodong, Hao, Miaomiao, Gao, Pujun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7536489/ https://www.ncbi.nlm.nih.gov/pubmed/32993424 http://dx.doi.org/10.1177/0300060520961916 |
Ejemplares similares
-
Prognostic risk factors for patients with hepatic sinusoidal obstruction syndrome caused by pyrrolizidine alkaloids
por: Du, Xiaofei, et al.
Publicado: (2023) -
Transjugular intrahepatic portosystemic shunt for pyrrolizidine alkaloid-related hepatic sinusoidal obstruction syndrome
por: Zhou, Chun-Ze, et al.
Publicado: (2020) -
Plateletcrit for predicting prognosis in patients with hepatic sinusoidal obstruction syndrome caused by pyrrolizidine alkaloid
por: Tu, Hongfei, et al.
Publicado: (2022) -
Validation of the Nanjing Criteria for Diagnosing Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstruction Syndrome
por: Zhang, Wei, et al.
Publicado: (2021) -
Diagnostic performance of Contrast-enhanced CT in Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstructive Syndrome
por: Kan, Xuefeng, et al.
Publicado: (2016)